Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 17/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1586067 | 1.00 | ALB (0.50) | ALBHCRTR1HCRTR2CYP1A2KCNH2 | |
| SCHEMBL27883288 | 0.88 | HCRTR1 (0.48) | HCRTR1HCRTR2CYP1A2KCNH2 | |
| SCHEMBL19484323 | 0.85 | ALDH1A1 (0.52) | HCRTR1HCRTR2CYP1A2KCNH2 | |
| SCHEMBL16025392 | 0.85 | HCRTR1 (0.49) | HCRTR1HCRTR2CYP1A2KCNH2 | |
| SCHEMBL18594639 | 0.81 | HCRTR1 (0.46) | HCRTR1HCRTR2CYP1A2KCNH2 | |
| SCHEMBL17071975 | 0.81 | HCRTR1 (0.46) | HCRTR1HCRTR2CYP1A2KCNH2 | |
| SCHEMBL17069765 | 0.81 | HCRTR1 (0.46) | HCRTR1HCRTR2CYP1A2KCNH2 | |
| SCHEMBL1652413 | 0.81 | ALDH1A1 (0.45) | HCRTR2NAPRT | |
| SCHEMBL31175258 | 0.79 | KDM4E (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL16277609 | 0.79 | CES2 (0.41) | ALBHCRTR1HCRTR2CYP1A2NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-11324724-B2 | N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11324724-B2 | N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides | HCRTR2, HCRTR1, CNR2 | ALB 4368/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.